~ Buy the DOPTELET (avatrombopag maleate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR DOPTELET

All Clinical Trials for Doptelet

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04312789 ↗	Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant	Recruiting	Dova Pharmaceuticals	Phase 2	2020-08-10	This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets.
NCT04312789 ↗	Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant	Recruiting	National Cancer Institute (NCI)	Phase 2	2020-08-10	This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets.
NCT04312789 ↗	Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant	Recruiting	Basem William, MD	Phase 2	2020-08-10	This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets.
NCT04312789 ↗	Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant	Recruiting	Ohio State University Comprehensive Cancer Center	Phase 2	2020-08-10	This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets.
NCT04516967 ↗	Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months	Recruiting	Dova Pharmaceuticals	Phase 3	2021-03-02	A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months

Clinical Trial Conditions for Doptelet

Condition Name

Condition Name for Doptelet
Intervention	Trials
Immune Thrombocytopenia	3
Thrombocytopenia; Drugs	2
Procedural Bleeding	1
Chronic Liver Disease	1

Condition MeSH

Condition MeSH for Doptelet
Intervention	Trials
Thrombocytopenia	6
Purpura, Thrombocytopenic, Idiopathic	3
Blood Platelet Disorders	1
Liver Diseases	1

Clinical Trial Locations for Doptelet

Trials by Country

Trials by Country for Doptelet
Location	Trials
United States	17
Turkey	4
Germany	2
France	2
Poland	2

Trials by US State

Trials by US State for Doptelet
Location	Trials
Ohio	2
Massachusetts	1
Illinois	1
Georgia	1
Florida	1

Clinical Trial Progress for Doptelet

Clinical Trial Phase

Clinical Trial Phase for Doptelet
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Doptelet
Clinical Trial Phase	Trials
Not yet recruiting	3
Recruiting	3
Withdrawn	1

Clinical Trial Sponsors for Doptelet

Sponsor Name

Sponsor Name for Doptelet
Sponsor	Trials
Dova Pharmaceuticals	3
National Cancer Institute (NCI)	1
Basem William, MD	1

Sponsor Type

Sponsor Type for Doptelet
Sponsor	Trials
Other	5
Industry	4
NIH	1